The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The potential future role of combination therapies with BTK inhibitors for mantle cell lymphoma
Krish Patel, MD, Sarah Cannon Cancer Institute, Nashville, TN, comments on the evolving role of combination therapies with BTK inhibitors (BTKi) in mantle cell lymphoma (MCL), highlighting the potential of chemo-free regimens, such as a BTKi paired with bispecific antibodies or BCL2 antagonists, which have shown promising activity in initial studies. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
I think one thing we’ve known about for many years now is BTK inhibitors play a really important role in mantle cell lymphoma. We’ve seen more mature data sets for their use in the frontline setting with the ECHO trial recently. And so I think one of the things that we’re really excited about are chemo-free combinations. So these combinations of BTK inhibitor with therapies like bispecific antibodies, with BCL2 antagonists...
I think one thing we’ve known about for many years now is BTK inhibitors play a really important role in mantle cell lymphoma. We’ve seen more mature data sets for their use in the frontline setting with the ECHO trial recently. And so I think one of the things that we’re really excited about are chemo-free combinations. So these combinations of BTK inhibitor with therapies like bispecific antibodies, with BCL2 antagonists. We’ve seen some smaller studies, signal finding studies, kind of Phase I, Phase II studies, which suggest these can be really highly active therapies, but we’re going to really need to develop these in larger settings to ultimately understand where should we be prioritizing chemo-free BTK combinations in frontline therapy for mantle cell.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Sunesis Pharmaceuticals: Consultancy, Research Funding; CRISPR Therapeutics: Research Funding; Fate Therapeutics: Research Funding; Genentech/Roche: Consultancy, Research Funding; MEI Pharma: Consultancy, Research Funding; Merck: Consultancy, Research Funding; Morphosys: Consultancy; AbbVie: Consultancy; Adaptive Biotechnologies: Research Funding; Nurix: Research Funding; Trillium Therapeutics/Pfizer: Consultancy, Research Funding; Pharmacyclics/Janssen: Consultancy, Research Funding; TG Therapeutics: Consultancy, Speakers Bureau; Kite: Consultancy, Research Funding, Speakers Bureau; Loxo Oncology: Consultancy, Research Funding; Epizyme: Consultancy, Research Funding; Curis, Inc: Research Funding; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; ADC Therapeutics: Consultancy; Xencor: Consultancy, Research Funding; BeiGene: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Caribou Biosciences: Consultancy.
